Co-Diagnostics, Inc. to Participate at FIME 2024 in Miami Beach, June 19-21

Rhea-AI Summary

Co-Diagnostics, a molecular diagnostics firm, will participate in the FIME 2024 trade show in Miami Beach, Florida from June 19-21. The company, known for its unique, patented platform for developing molecular diagnostic tests, will be hosted at the Utah booth. FIME is a premier medical trade expo attracting over 15,000 professionals and exhibitors from 116 countries. Co-Diagnostics will showcase its new Co-Dx PCR platform, which is under review by the FDA for Over-the-Counter (OTC) clearance. Attendees can visit Booth S61 to learn more about Co-Dx products, including the Co-Dx PCR Pro instrument and associated tests, which are currently under FDA review but not yet available for sale.

SALT LAKE CITY, June 18, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company has been invited to participate in the Utah booth at the FIME trade show in Miami Beach, Florida, on June 19-21.

FIME is described as the Americas' leading medical trade expo for medical device and product purchasers, for establishing new supplier relationships, and for strengthening business ties with the global medical device and equipment market, with exhibitors from 116 countries and more than 15,000 expected professional attendees.

The Company will be participating in the Utah booth, displaying the new Co-Dx™ PCR platform*, for which a 510(k) application has been recently submitted to the U.S. Food and Drug Administration for OTC clearance.

To learn more about the event, please visit here. Attendees interested in learning more about Co-Dx and its products, including its upcoming Co-Dx PCR Pro instrument and tests, are invited to visit the Company at Booth S61.

*The Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale. The Co-Dx PCR Pro instrument and Co-Dx COVID-19 Test are currently under review by the FDA.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to locate genetic markers for use in applications other than infectious disease.

View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-participate-at-fime-2024-in-miami-beach-june-19-21-302175867.html

SOURCE Co-Diagnostics

FAQ

What event is Co-Diagnostics participating in during June 2024?

Co-Diagnostics is participating in the FIME 2024 trade show in Miami Beach, Florida from June 19-21, 2024.

What will Co-Diagnostics showcase at the FIME 2024 trade show?

Co-Diagnostics will showcase its Co-Dx PCR platform, which includes the PCR Home, PCR Pro, and a mobile app, at the FIME 2024 trade show.

Where can attendees find Co-Diagnostics at the FIME 2024 trade show?

Attendees can find Co-Diagnostics at Booth S61 during the FIME 2024 trade show.

What FDA clearances is Co-Diagnostics seeking for its Co-Dx PCR platform?

Co-Diagnostics is seeking FDA Over-the-Counter (OTC) clearance for its Co-Dx PCR platform, including the Co-Dx PCR Pro instrument and associated tests.

How many professional attendees are expected at FIME 2024?

Over 15,000 professional attendees are expected at FIME 2024.

How many countries will be represented by exhibitors at FIME 2024?

Exhibitors from 116 countries will be represented at FIME 2024.

What is the stock symbol for Co-Diagnostics?

The stock symbol for Co-Diagnostics is CODX.